About Zacharon Pharmaceuticals
Zacharon Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 2004, and was acquired by BioMarin Pharmaceutical in January 2013. Small molecule therapeutics targeting glycan biosynthesis are developed. Zacharon Pharmaceuticals has raised $4.05 million across 11 funding rounds from investors including BioMarin Pharmaceutical, NIH and HHS. Its chief executive, as recorded, is Robin M Jackman. Zacharon Pharmaceuticals offers products and services including Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is Zacharon Pharmaceuticals, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Zacharon Pharmaceuticals was founded in 2004 in San Diego, United States, within the biotechnology sector. Small molecule therapeutics were developed to target glycan biosynthesis, supported by a platform integrating cell-based screening and glycan structural analysis for drug discovery. Programs addressed heparan sulfate inhibitors for mucopolysaccharidosis III and ganglioside inhibitors for Tay-Sachs and Sandhoff diseases. Acquisition by BioMarin occurred in January 2013 for 10 million.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website zacharon.com
- Social LinkedIn
- Acquired by BioMarin Pharmaceutical (Jan 2013)
- Legal Name Zacharon Pharmaceuticals, Inc
- Total Equity Funding$4.05M (USD)
in 11 rounds
- Latest Funding Round$33K (USD), Series A
Mar 2012
- InvestorsBioMarin Pharmaceutical
& 3 more
- Acquired byBioMarin Pharmaceutical
(Jan 2013)
Products & Services of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals offers a comprehensive portfolio of products and services, including Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay.
Small molecule drugs for treating lysosomal storage diseases and cancer.
Platform for discovering glycan-targeted treatments via screening.
Assay for detecting lysosomal storage diseases through partnerships.
Funding Insights of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has successfully raised a total of $4.05M across 11 strategic funding rounds. The most recent funding activity was a Series A round of $33 thousand completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.05M
- Total Rounds 11
- Last Round Series A — $33,000
- First Round $1.63M
(Sep 2008)
- Investors Count 3
Latest 10 of 11 funding rounds of Zacharon Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2012 | $33,000 | Series A | – | – | – |
| Mar 2012 | $335,739 | Grant | – | – | |
| May 2011 | $2M | Grant | – | – | |
| Mar 2011 | $15,001 | Series A | – | – | – |
| Jan 2011 | $342,896 | Grant | – | – | |
| Sep 2010 | $1.63M | Grant | – | – | |
| Jun 2010 | $500,000 | Series A | – | – | – |
| May 2010 | $339,513 | Grant | – | – | |
| Nov 2008 | $3.5M | Series A | – | – | |
| Sep 2008 | $188,112 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| avalonbioventures.com | ||||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | 1997 | biomarin.com | San Rafael, United States |
Investor details for Zacharon Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zacharon Pharmaceuticals
1 people are tracked at Zacharon Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Robin M Jackman | CEO & President | Leadership |
Complete people profiles for Zacharon Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zacharon Pharmaceuticals
4 dated milestones of Zacharon Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Zacharon Pharmaceuticals is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Series A, of $33K.
- Exit Acquired by BioMarin Pharmaceutical.
Competitors of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Zacharon Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Zacharon Pharmaceuticals (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Zacharon Pharmaceuticals
Zacharon Pharmaceuticals was founded in 2004 and raised its 1st funding round 4 years after it was founded.
Zacharon Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Robin M Jackman is the CEO of Zacharon Pharmaceuticals, as recorded in our data.
Zacharon Pharmaceuticals is a funded company, having raised a total of $4.05M across 11 funding rounds to date. The company's 1st funding round was a Grant of $188.11K, raised on Sep 2008.
Zacharon Pharmaceuticals was founded in 2004 in San Diego, United States, within the biotechnology sector. Small molecule therapeutics were developed to target glycan biosynthesis, supported by a platform integrating cell-based screening and glycan structural analysis for drug discovery. Programs addressed heparan sulfate inhibitors for mucopolysaccharidosis III and ganglioside inhibitors for Tay-Sachs and Sandhoff diseases. Acquisition by BioMarin occurred in January 2013 for 10 million.
Zacharon Pharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Zacharon Pharmaceuticals offers Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay.
Zacharon Pharmaceuticals has 4 investors. Key investors include BioMarin Pharmaceutical, NIH, HHS, and Avalon Bio Ventures.
Zacharon Pharmaceuticals operates through Zacharon Pharmaceuticals, Inc.
Yes. Zacharon Pharmaceuticals was acquired by BioMarin Pharmaceutical in January 2013.